Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495069 | 1.00 | THRB (0.43) | THRBMEN1KMT2ANOS2 | |
| SCHEMBL867906 | 1.00 | THRB (0.43) | THRBMEN1KMT2ANOS2 | |
| SCHEMBL19774047 | 0.95 | — | — | |
| SCHEMBL21288425 | 0.95 | THRB (0.50) | THRBMEN1KMT2A | |
| SCHEMBL21511110 | 0.95 | — | — | |
| SCHEMBL1276256 | 0.95 | — | — | |
| SCHEMBL18231970 | 0.95 | THRB (0.40) | THRBMEN1KMT2ANOS2 | |
| SCHEMBL17875148 | 0.95 | THRB (0.40) | THRBMEN1KMT2ANOS2 | |
| Cyclopentanamine SCHEMBL9209573 | 0.95 | THRB (0.50) | THRBMEN1KMT2A | |
| SCHEMBL16479 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472170-B1 | TROGER'S BASE-BASED MONOMERS, AND POLYMERS, METHODS OF MAKING AND USES THEREOF | UNIV KING ABDULLAH SCI & TECH (SA) | 2023-10-18 | — | — | EP | disclosed |
| US-20230178854-A1 | WATER BASED POLYIMIDE-POWDER COATING COMPOSITION AND METHOD FOR MANUFACTURING COMPOSITE SEPARATOR FOR LITHIUM SECONDARY BATTERY USING SAME | XERABRID CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-11401382-B2 | Thermoplastic polyamide particles | BASF SE (DE) | 2022-08-02 | — | — | US | disclosed |
| CN-109415507-B | Thermoplastic polyamide particles | 巴斯夫欧洲公司 | 2022-03-08 | — | — | CN | disclosed |
| US-11027242-B2 | Nanofiltration membranes and methods of use | NOVOMER, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210147628-A1 | HYDROPHILIC POLYIMIDE, MEMBRANES PREPARED THEREFROM, AND USES THEREOF | KYOTO UNIVERSITY (JP) | 2021-05-20 | — | — | US | disclosed |
| EP-3448916-B1 | THERMOPLASTIC POLYAMIDE PARTICLES | BASF SE (DE) | 2020-10-14 | — | — | EP | disclosed |
| EP-2520972-B1 | Liquid crystal display device alignment film, and method for manufacturing the same | SAMSUNG DISPLAY CO LTD (KR) | 2019-09-04 | — | — | EP | disclosed |
| US-20190255488-A1 | NANOFILTRATION MEMBRANES AND METHODS OF USE | NOVOMER, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190127527-A1 | THERMOPLASTIC POLYAMIDE PARTICLES | BASF GRENZACH GMBH (DE) | 2019-05-02 | — | — | US | disclosed |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| EP-0140324-B1 | POLYARYLENE SULFIDES WITH REDUCED CORROSIVENESS | BAYER AG (DE) | 1989-06-21 | — | — | EP | disclosed |
| US-4609699-A | AMINE STABILIZER | BAYER AKTIENGESELLSCHAFT (DE) | 1986-09-02 | — | — | US | disclosed |
| EP-0140324-A2 | Polyarylene sulfides with reduced corrosiveness | BAYER AG (DE) | 1985-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255488-A1 | NANOFILTRATION MEMBRANES AND METHODS OF USE | MLEC, EPCAM, LNPK | THRB 4727/4885MEN1 1683/4885KMT2A 4343/4885 |
| US-11027242-B2 | Nanofiltration membranes and methods of use | MLEC, EPCAM, LNPK | THRB 4727/4885MEN1 1683/4885KMT2A 4343/4885 |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | THRB 578/4885MEN1 662/4885KMT2A 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.